<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">inovmed</journal-id><journal-title-group><journal-title xml:lang="ru">Инновационная медицина Кубани</journal-title><trans-title-group xml:lang="en"><trans-title>Innovative Medicine of Kuban</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2541-9897</issn><publisher><publisher-name>Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35401/2541-9897-2026-11-2-32-37</article-id><article-id custom-type="elpub" pub-id-type="custom">inovmed-1523</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Связь полиморфизма гена MMP-9 rs3918242 (C-1562T) с клинико-патологическими особенностями при люминальном подтипе рака молочной железы</article-title><trans-title-group xml:lang="en"><trans-title>The Relationship of MMP-9 Gene Polymorphism rs3918242 (C-1562T) with Clinical-Pathological Features in Luminal Subtype Breast Cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8952-3347</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новианти</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Novianti</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Путу Астри Новианти - MD, MSs (биохимия), хирург, научный сотрудник, кафедра хирургии, факультет медицины.</p><p>Денпасар</p></bio><bio xml:lang="en"><p>Putu Astri Novianti - MD, MSs (Biomedical Science), General Surgeon, Researcher, Department of Surgery, Faculty of Medicine.</p><p>Denpasar</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2676-8037</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Адипутра</surname><given-names>П. А.Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Adiputra</surname><given-names>P. A.T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Путу Анда Туста Адипутра - д. м. н., профессор, FinaCS, FICS, старший хирург-онколог, научный сотрудник в области онкологии, кафедра хирургии, медицинский факультет.</p><p>Ул. PB Судирмана, Денпасар, Бали</p></bio><bio xml:lang="en"><p>Putu Anda Tusta Adiputra - Dr. Sci. (Med.), Prof., FinaCS, FICS, Senior Oncological Surgeon, Oncological Researcher, Department of Surgery, Faculty of Medicine.</p><p>PB Sudirman Street, Denpasar, Bali</p></bio><email xlink:type="simple">Novianti85@unud.ac.id</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1577-0465</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Супадманаба</surname><given-names>И Г.П.</given-names></name><name name-style="western" xml:lang="en"><surname>Supadmanaba</surname><given-names>I G.P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>И Геде Путу Супадманаба - MD, M.Sc, старший научный сотрудник в области онкологии, кафедра биохимии, факультет медицины.</p><p>Денпасар</p></bio><bio xml:lang="en"><p>I Gede Putu Supadmanaba - MD, M.Sc, Senior Oncology Research Scientist, Department of Biochemistry, Faculty of Medicine.</p><p>Denpasar</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6493-1849</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кусума</surname><given-names>И К.В.А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kusuma</surname><given-names>I K.W.A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>И Команг Вира Ананта Кусума - MBBS, младший научный сотрудник в области онкологии, медицинский факультет.</p><p>Денпасар</p></bio><bio xml:lang="en"><p>I Komang Wira Ananta Kusuma - MBBS, Junior Oncology Research Scientist, Faculty of Medicine.</p><p>Denpasar</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0593-4086</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сасмана</surname><given-names>И Г.А.П.</given-names></name><name name-style="western" xml:lang="en"><surname>Sasmana</surname><given-names>I G.A.P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>И Геде Асвин Парисья Сасмана - MBBS, младший научный сотрудник в области онкологии, факультет медицины.</p><p>Денпасар</p></bio><bio xml:lang="en"><p>I Gede Aswin Parisya Sasmana - MBBS, Junior Oncology Research Scientist, Faculty of Medicine.</p><p>Denpasar</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4558-1454</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деви</surname><given-names>А. А.Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Devy</surname><given-names>A.A.T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ангги Аманда Триана Деви - MBBS, младший научный сотрудник в области онкологии, факультет медицины.</p><p>Денпасар</p></bio><bio xml:lang="en"><p>Anggi Amanda Triana Devy - MBBS, Junior Oncology Research Scientist, Faculty of Medicine.</p><p>Denpasar</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5364-1969</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вираната</surname><given-names>С.</given-names></name><name name-style="western" xml:lang="en"><surname>Wiranata</surname><given-names>S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Синта Вираната - MD, младший научный сотрудник в области нейрохирургии, факультет медицины.</p><p>Денпасар</p></bio><bio xml:lang="en"><p>Sinta Wiranata - MD, Junior Neurosurgery Research Scientist, Faculty of Medicine.</p><p>Denpasar</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Университет Удаяна</institution><country>Индонезия</country></aff><aff xml:lang="en"><institution>Udayana University</institution><country>Indonesia</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>22</day><month>05</month><year>2026</year></pub-date><volume>11</volume><issue>2</issue><fpage>32</fpage><lpage>37</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Новианти П.А., Адипутра П.А., Супадманаба И.Г., Кусума И.К., Сасмана И.Г., Деви А.А., Вираната С., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Новианти П.А., Адипутра П.А., Супадманаба И.Г., Кусума И.К., Сасмана И.Г., Деви А.А., Вираната С.</copyright-holder><copyright-holder xml:lang="en">Novianti P.A., Adiputra P.A., Supadmanaba I.G., Kusuma I.K., Sasmana I., Devy A., Wiranata S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.innovmedkub.ru/jour/article/view/1523">https://www.innovmedkub.ru/jour/article/view/1523</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность: Рак молочной железы представляет собой злокачественное новообразование, развивающееся из протокового и долькового эпителия. Полиморфизм rs3918242 гена матриксной металлопротеиназы-9 (MMP-9) рассматривается как генетический фактор, влияющий на пролиферацию опухолевых клеток и прогрессирование опухоли. Целью настоящего исследования является изучение связи полиморфизма гена ММР-9 rs3918242 (C-1562T) и клинико-патологических характеристик люминального подтипа рака молочной железы.</p></sec><sec><title>Методы</title><p>Методы: Данное исследование относится к категории описательно-аналитических исследований с поперечным дизайном. Для выявления полиморфизма гена ММР-9 rs3918242 (C-1562T) в образцах крови пациентов использовали метод полимеразной цепной реакции. Статистическая обработка данных проводилась с использованием программного обеспечения SPSS версии 26.0.</p></sec><sec><title>Результаты</title><p>Результаты: Средний возраст участников, возраст на момент постановки диагноза и возраст менархе составили 55,67±10,64, 53,29±10,28 и 13,48±1,60 года соответственно. У большинства пациентов число родов было менее двух (54,8%), при этом преобладали женщины в постменопаузе (19 пациентов, 64,5%). Большинство случаев относилось к ранним стадиям рака молочной железы (19 образцов 61,3%), при этом гистологический анализ выявил преобладание образцов высокой степени злокачественности (23 образца, 74,2%). Бивариантный анализ продемонстрировал статистически значимую связь между полиморфизмом гена ММР-9 rs3918242 (C-1562T) и клинико-патологическими особенностями люминального подтипа рака молочной железы, включая стадию заболевания и наличие метастазов.</p></sec><sec><title>Заключение</title><p>Заключение: Выявлена статистически значимая связь между полиморфизмом гена ММР-9 rs3918242 и клинико-патологическими характеристиками пациентов с люминальным подтипом рака молочной железы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background: Breast cancer is a malignant tumor arising from the ductal or lobular epithelium. The Matrix Metalloproteinase-9 (MMP-9) rs3918242 polymorphism has been reported as a genetic factor influencing cancer cell proliferation and tumor progression. Therefore, this study aims to investigate the association between the MMP-9 rs3918242 (C-1562T) gene polymorphism and the clinicopathology of luminal subtype breast cancer.</p></sec><sec><title>Methods</title><p>Methods: This study is a descriptive-analytic research with a cross-sectional design. The polymerase chain reaction (PCR) method was used to detect the MMP-9 rs3918242 (C-1562T) gene polymorphism in patients’ blood samples. Data were analyzed using SPSS version 26.0.</p></sec><sec><title>Results</title><p>Results: The mean age of the participants, age at diagnosis, and age at menarche were 55.67±10.64, 53.29±10.28, and 13.48±1.60 years, respectively. Most participants had fewer than 2 childbirths (54.8%), and the majority were postmenopausal (64.5%). Regarding tumor characteristics, most cases were early-stage breast cancer (19 patients, 61.3%), while histological grading showed a predominance of high-grade tumors (23 patients, 74.2%). Bivariate analysis revealed a significant association between the MMP-9 rs3918242 (C-1562T) gene polymorphism and the clinicopathological features of luminal subtype breast cancer, including stage and metastasis.</p></sec><sec><title>Conclusion</title><p>Conclusion: A significant association was identified between the MMP-9 rs3918242 gene polymorphism and the clinicopathological characteristics of patients with luminal subtype breast cancer.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>люминальный подтип рака молочной железы</kwd><kwd>клинико-патология</kwd><kwd>полиморфизм ММР-9</kwd></kwd-group><kwd-group xml:lang="en"><kwd>luminal subtype breast cancer</kwd><kwd>clinicopathology</kwd><kwd>MMP-9 polymorphism</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке Института исследований и общественных услуг Университета Удаяна в рамках программы исследовательских грантов. Благодарность: Авторы выражают благодарность пациентам с диагнозом рак молочной железы, участвовавшим в данном исследовании, кафедрам биохимии и хирургии медицинского факультета Университета Удаяна, а также интегрированной биомедицинской лаборатории за содействие в проведении исследования</funding-statement><funding-statement xml:lang="en">This study was funded by the Institute for Research and Community Service at Udayana University under a research grant scheme. Authors would like to thank the breast cancer patients who participated in this research, the Department of Biochemistry and the Department of Surgery, Faculty of Medicine, Udayana University, and the integrated biomedical laboratory during the implementation of the research</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Brufsky A, Miles D, Zvirbule Z, Eniu A, Lopez-Miranda E, Seo J, et al. Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I. Cancer Research. American Association for Cancer Research. 2018;78(4Supplement):P5-21-01.</mixed-citation><mixed-citation xml:lang="en">Brufsky A, Miles D, Zvirbule Z, Eniu A, Lopez-Miranda E, Seo J, et al. Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I. Cancer Research. American Association for Cancer Research. 2018;78(4Supplement):P5-21-01.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Papaoiconomou E, Lymperi M, Petraki C, et al. Kiss-1/ GPR54 protein expression in breast cancer. Anticancer Res. 2014;34(3):1401-1407. PMID: 24596387</mixed-citation><mixed-citation xml:lang="en">Papaoiconomou E, Lymperi M, Petraki C, et al. Kiss-1/ GPR54 protein expression in breast cancer. Anticancer Res. 2014;34(3):1401-1407. PMID: 24596387</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106. PMID: 30258937. PMCID: PMC6147049. https://doi.org/10.1016/j.gendis.2018.05.001</mixed-citation><mixed-citation xml:lang="en">Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106. PMID: 30258937. PMCID: PMC6147049. https://doi.org/10.1016/j.gendis.2018.05.001</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jana S, Madhu Krishna B, Singhal J, et al. SOX9: The master regulator of cell fate in breast cancer. Biochem Pharmacol. 2020;174:113789. PMID: 31911091. PMCID: PMC9048250. https://doi.org/10.1016/j.bcp.2019.113789</mixed-citation><mixed-citation xml:lang="en">Jana S, Madhu Krishna B, Singhal J, et al. SOX9: The master regulator of cell fate in breast cancer. Biochem Pharmacol. 2020;174:113789. PMID: 31911091. PMCID: PMC9048250. https://doi.org/10.1016/j.bcp.2019.113789</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sasmana I, Putri P, Dewi N, Supadmanaba I, Wihandani D. Current Development of Virotherapy in Breast Cancer: A Brief Review. Acta Medica Bulg. 2024;51(4):86–94. https://doi.org/10.2478/AMB-2024-0084</mixed-citation><mixed-citation xml:lang="en">Sasmana I, Putri P, Dewi N, Supadmanaba I, Wihandani D. Current Development of Virotherapy in Breast Cancer: A Brief Review. Acta Medica Bulg. 2024;51(4):86–94. https://doi.org/10.2478/AMB-2024-0084</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">International Agency for Research on Cancer (IARC). Indonesia – Global Cancer Observatory. Globocan. 2020;858:1–2.</mixed-citation><mixed-citation xml:lang="en">International Agency for Research on Cancer (IARC). Indonesia – Global Cancer Observatory. Globocan. 2020;858:1–2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Society AC. Breast Cancer Fact and Figures 2017-2018. 2018. Available by: https://www.cancer.org/research/cancer-factsstatistics/breast-cancer-facts-figures.html</mixed-citation><mixed-citation xml:lang="en">Society AC. Breast Cancer Fact and Figures 2017-2018. 2018. Available by: https://www.cancer.org/research/cancer-factsstatistics/breast-cancer-facts-figures.html</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):6502465033. PMID: 27542253. PMCID: PMC5323135. https://doi.org/10.18632/oncotarget.11344</mixed-citation><mixed-citation xml:lang="en">Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):6502465033. PMID: 27542253. PMCID: PMC5323135. https://doi.org/10.18632/oncotarget.11344</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017;3(1):5–11. https://doi.org/10.1016/j.jons.2017.01.001</mixed-citation><mixed-citation xml:lang="en">Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017;3(1):5–11. https://doi.org/10.1016/j.jons.2017.01.001</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sasmana IGAP, Wiranata S, Yogananda KC, Wihandani DM, Supadmanaba IGP. Clinicopathological and Prognostic Significance of SRY-Box Transcription Factor 2 (SOX2) Overexpression in Central Nervous System Tumor : A Meta-Analysis. Bali Med J. 2023;12(2):1733–9. https://doi.org/10.15562/bmj.v12i2.4493</mixed-citation><mixed-citation xml:lang="en">Sasmana IGAP, Wiranata S, Yogananda KC, Wihandani DM, Supadmanaba IGP. Clinicopathological and Prognostic Significance of SRY-Box Transcription Factor 2 (SOX2) Overexpression in Central Nervous System Tumor : A Meta-Analysis. Bali Med J. 2023;12(2):1733–9. https://doi.org/10.15562/bmj.v12i2.4493</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jafari R, Majidi Zolbanin N, Majidi J, et al. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. Iran Biomed J. 2019;23(1):21-33. PMID: 30041514. PMCID: PMC6305820. https://doi.org/10.29252/.23.1.21</mixed-citation><mixed-citation xml:lang="en">Jafari R, Majidi Zolbanin N, Majidi J, et al. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. Iran Biomed J. 2019;23(1):21-33. PMID: 30041514. PMCID: PMC6305820. https://doi.org/10.29252/.23.1.21</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Platonov ME, Borovjagin AV, Kaverina N, et al. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer Lett. 2018;417:75-88. PMID: 29269086. https://doi.org/10.1016/j.canlet.2017.12.024</mixed-citation><mixed-citation xml:lang="en">Platonov ME, Borovjagin AV, Kaverina N, et al. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer Lett. 2018;417:75-88. PMID: 29269086. https://doi.org/10.1016/j.canlet.2017.12.024</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lin BW, Gong CC, Song HF, Cui YY. Effects of anthocyanins on the prevention and treatment of cancer. Br J Pharmacol. 2017;174(11):1226-1243. PMID: 27646173. PMCID: PMC5429338. https://doi.org/10.1111/bph.13627</mixed-citation><mixed-citation xml:lang="en">Lin BW, Gong CC, Song HF, Cui YY. Effects of anthocyanins on the prevention and treatment of cancer. Br J Pharmacol. 2017;174(11):1226-1243. PMID: 27646173. PMCID: PMC5429338. https://doi.org/10.1111/bph.13627</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Huang H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel). 2018;18(10):3249. PMID: 30262739. PMCID: PMC6211011. https://doi.org/10.3390/s18103249</mixed-citation><mixed-citation xml:lang="en">Huang H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel). 2018;18(10):3249. PMID: 30262739. PMCID: PMC6211011. https://doi.org/10.3390/s18103249</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rahimi Z, Yari K, Rahimi Z. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev. 2015;16(3):1175-1179. PMID: 25735351. https://doi.org/10.7314/apjcp.2015.16.3.1175</mixed-citation><mixed-citation xml:lang="en">Rahimi Z, Yari K, Rahimi Z. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev. 2015;16(3):1175-1179. PMID: 25735351. https://doi.org/10.7314/apjcp.2015.16.3.1175</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Xu T, Zhang S, Qiu D, Li X, Fan Y. Association between matrix metalloproteinase 9 polymorphisms and breast cancer risk: An updated meta-analysis and trial sequential analysis. Gene. 2020;759:144972. PMID: 32739585. https://doi.org/10.1016/j.gene.2020.144972</mixed-citation><mixed-citation xml:lang="en">Xu T, Zhang S, Qiu D, Li X, Fan Y. Association between matrix metalloproteinase 9 polymorphisms and breast cancer risk: An updated meta-analysis and trial sequential analysis. Gene. 2020;759:144972. PMID: 32739585. https://doi.org/10.1016/j.gene.2020.144972</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Caykara B, Alsaadoni H, Pençe S, Pençe HH, Ötünçtemur A. Investigation of MMP-9 rs3918242 and TIMP2 rs8179090 polymorphisms in renal cell carcinoma tissues. Turkish J Biochem. 2020;45(4):429–34.</mixed-citation><mixed-citation xml:lang="en">Caykara B, Alsaadoni H, Pençe S, Pençe HH, Ötünçtemur A. Investigation of MMP-9 rs3918242 and TIMP2 rs8179090 polymorphisms in renal cell carcinoma tissues. Turkish J Biochem. 2020;45(4):429–34.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sutadarma IWG, Supadmanaba IGP, Adiputra PAT, Devy AAT, Indrakusuma AABP, Sasmana IGAP. Relationship Between XRCC1 Arg399gln Polymorphism and Risk of Luminal Subtype Breast Cancer in Bali, Indonesia. Acta Medica (Hradec Kralove). 2025;68(1):21-25. PMID: 40521603. https://doi.org/10.14712/18059694.2025.14</mixed-citation><mixed-citation xml:lang="en">Sutadarma IWG, Supadmanaba IGP, Adiputra PAT, Devy AAT, Indrakusuma AABP, Sasmana IGAP. Relationship Between XRCC1 Arg399gln Polymorphism and Risk of Luminal Subtype Breast Cancer in Bali, Indonesia. Acta Medica (Hradec Kralove). 2025;68(1):21-25. PMID: 40521603. https://doi.org/10.14712/18059694.2025.14</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Felizi RT, Veiga MG, Carelli Filho I, Souto RPD, Fernandes CE, Oliveira E. Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk. Associação entre o polimorfismo do gene metalopeptidase de matriz 9 e o risco de câncer de mama. Rev Bras Ginecol Obstet. 2018;40(10):620624. PMID: 30352460. PMCID: PMC10316932. https://doi.org/10.1055/s-0038-1673366</mixed-citation><mixed-citation xml:lang="en">Felizi RT, Veiga MG, Carelli Filho I, Souto RPD, Fernandes CE, Oliveira E. Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk. Associação entre o polimorfismo do gene metalopeptidase de matriz 9 e o risco de câncer de mama. Rev Bras Ginecol Obstet. 2018;40(10):620624. PMID: 30352460. PMCID: PMC10316932. https://doi.org/10.1055/s-0038-1673366</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Subiyanto D, Kadi TA, Ismaiyah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Subtipe Molekuler Kanker Payudara di RSUD Madiun dan Hubungannya dengan Grading Histopatologi. Media Penelitian dan Pengembangan Kesehatan. 2021;31(3):193– 202. https://doi.org/10.22435/mpk.v31i3.4986</mixed-citation><mixed-citation xml:lang="en">Subiyanto D, Kadi TA, Ismaiyah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Subtipe Molekuler Kanker Payudara di RSUD Madiun dan Hubungannya dengan Grading Histopatologi. Media Penelitian dan Pengembangan Kesehatan. 2021;31(3):193– 202. https://doi.org/10.22435/mpk.v31i3.4986</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Abd Elmaogoud Ragab Ibrahim F, Essam Elfeky S, Haroun M, et al. Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case-control study. Mol Clin Oncol. 2020;13(1):54-62. PMID: 32454974. PMCID: PMC7241239. https://doi.org/10.3892/mco.2020.2041</mixed-citation><mixed-citation xml:lang="en">Abd Elmaogoud Ragab Ibrahim F, Essam Elfeky S, Haroun M, et al. Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case-control study. Mol Clin Oncol. 2020;13(1):54-62. PMID: 32454974. PMCID: PMC7241239. https://doi.org/10.3892/mco.2020.2041</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kimi L, Ghatak S, Yadav RP, et al. Relevance of GSTM1, GSTT1 and GSTP1 Gene Polymorphism to Breast Cancer Susceptibility in Mizoram Population, Northeast India. Biochem Genet. 2016;54(1):41-49. PMID: 26407578. https://doi.org/10.1007/s10528-015-9698-5</mixed-citation><mixed-citation xml:lang="en">Kimi L, Ghatak S, Yadav RP, et al. Relevance of GSTM1, GSTT1 and GSTP1 Gene Polymorphism to Breast Cancer Susceptibility in Mizoram Population, Northeast India. Biochem Genet. 2016;54(1):41-49. PMID: 26407578. https://doi.org/10.1007/s10528-015-9698-5</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34-74. PMID: 24269963. https://doi.org/10.1016/j.phrs.2013.11.002</mixed-citation><mixed-citation xml:lang="en">Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34-74. PMID: 24269963. https://doi.org/10.1016/j.phrs.2013.11.002</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22(2):139-143. PMID: 23566435. https://doi.org/10.1016/j.suronc.2013.03.001</mixed-citation><mixed-citation xml:lang="en">Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22(2):139-143. PMID: 23566435. https://doi.org/10.1016/j.suronc.2013.03.001</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Szecsi PB, Larsen J, Hørby J, Axelsson CK. Seroma production after breast cancer surgery has a pro-inflammatory component. Open Breast Cancer J. 2012;4:11–7. https://doi.org/10.2174/1876817201204010011</mixed-citation><mixed-citation xml:lang="en">Szecsi PB, Larsen J, Hørby J, Axelsson CK. Seroma production after breast cancer surgery has a pro-inflammatory component. Open Breast Cancer J. 2012;4:11–7. https://doi.org/10.2174/1876817201204010011</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">O Bryan SM, Mathis JM. Oncolytic Virotherapy for Breast Cancer Treatment. Curr Gene Ther. 2018;18(4):192-205. PMID: 30207220. PMCID: PMC7499349. https://doi.org/10.2174/1566523218666180910163805</mixed-citation><mixed-citation xml:lang="en">O Bryan SM, Mathis JM. Oncolytic Virotherapy for Breast Cancer Treatment. Curr Gene Ther. 2018;18(4):192-205. PMID: 30207220. PMCID: PMC7499349. https://doi.org/10.2174/1566523218666180910163805</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Zahra Dehghan Manshadi, Mohammad Hamid FK, Heidar Tayebinia IK. Metalloproteinase Gene Polymorphisms Metastasis in Women with Breast Cancer in Central Iran. 2018;9:123–31.</mixed-citation><mixed-citation xml:lang="en">Zahra Dehghan Manshadi, Mohammad Hamid FK, Heidar Tayebinia IK. Metalloproteinase Gene Polymorphisms Metastasis in Women with Breast Cancer in Central Iran. 2018;9:123–31.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
